Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endoscopic nasopharyngectomy with or without postoperative gemcitabine + cisplatin for recurrent nasopharyngeal carcinoma
ChiCTR2000035835Phase 2Not yet recruiting
- Sponsor
- Eye and ENT Hospital of Fudan University
- Start
- Oct 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of gemcitabine and cisplatin in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Eye and ENT Hospital of Fudan University. Primary endpoints: Overall survival and Quality of life. Planned start Oct 2020; status: not yet recruiting.
02
Drugs
gemcitabinecisplatin
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on ChiCTR2000035835.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035835.